Marks Group Wealth Management Inc Cuts Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Marks Group Wealth Management Inc lessened its stake in IQVIA Holdings Inc. (NYSE:IQV) by 0.4% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 34,466 shares of the medical research company’s stock after selling 136 shares during the quarter. Marks Group Wealth Management Inc’s holdings in IQVIA were worth $6,773,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in IQV. FMR LLC lifted its stake in IQVIA by 38.7% in the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after acquiring an additional 804,963 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in shares of IQVIA in the 3rd quarter valued at $147,683,000. JPMorgan Chase & Co. lifted its position in shares of IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after purchasing an additional 583,396 shares during the last quarter. Nordea Investment Management AB increased its holdings in IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after buying an additional 452,029 shares during the last quarter. Finally, KBC Group NV raised its stake in IQVIA by 68.5% in the fourth quarter. KBC Group NV now owns 616,299 shares of the medical research company’s stock valued at $121,109,000 after buying an additional 250,458 shares in the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on IQV. JPMorgan Chase & Co. lowered their price objective on IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th. Morgan Stanley upped their price target on IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a report on Tuesday. Truist Financial reissued a “buy” rating and set a $263.00 price objective (up previously from $261.00) on shares of IQVIA in a report on Monday. Stifel Nicolaus dropped their target price on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Finally, Stephens assumed coverage on shares of IQVIA in a research report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price target for the company. Five research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $251.67.

Insider Transactions at IQVIA

In other IQVIA news, Director John G. Danhakl acquired 1,275 shares of the company’s stock in a transaction that occurred on Tuesday, December 3rd. The shares were purchased at an average price of $200.58 per share, with a total value of $255,739.50. Following the completion of the acquisition, the director now directly owns 1,275 shares of the company’s stock, valued at approximately $255,739.50. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 1.60% of the company’s stock.

IQVIA Price Performance

IQVIA stock opened at $200.94 on Wednesday. The business has a 50 day simple moving average of $200.77 and a 200-day simple moving average of $219.09. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.81. The stock has a market capitalization of $36.47 billion, a PE ratio of 26.79, a price-to-earnings-growth ratio of 2.25 and a beta of 1.48.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities analysts predict that IQVIA Holdings Inc. will post 10.81 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.